Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Clinical trial NCT07096778 · RECRUITING

Trial details

NCT number: NCT07096778
Sponsor: CellCentric Ltd.
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Multiple Myeloma Refractory Multiple Myeloma in Relapse

Start date: 2026-01-22
Primary completion: 2029-12-01
Enrollment: 100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.